Daniel Cruz, MD
Advanced Heart Failure and Transplant Cardiology · Los Angeles, CANPI 1427090091
Payments from drug & device makers
Across 9 payments — averaging $292.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$2K
- Cvrx, Inc.$353
- Abbott$263
- Edwards Lifesciences$172
- Endotronix, Inc.$142
What the payments were for
- Speaking & faculty fees$1,70065%
- Food & beverage$93035%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 3 | $1,700 |
| Cvrx, Inc. | 2 | $353 |
| Abbott | 2 | $263 |
| Edwards Lifesciences | 1 | $172 |
| Endotronix, Inc. | 1 | $142 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,630 in reported general payments places this provider in the 20th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 151 | $4,588,397 |
| EntrestoSacubitril/Valsartan | 330 | $375,038 |
| EliquisApixaban | 345 | $373,808 |
| FarxigaDapagliflozin Propanediol | 171 | $188,183 |
| JardianceEmpagliflozin | 157 | $140,679 |
| XareltoRivaroxaban | 60 | $63,614 |
| Repatha SureclickEvolocumab | 33 | $26,398 |
| BrilintaTicagrelor | 34 | $16,509 |
| Repatha SyringeEvolocumab | 11 | $10,338 |
| CorlanorIvabradine Hcl | 13 | $9,127 |
| Potassium Chloride | 214 | $8,137 |
| Metoprolol Succinate | 422 | $7,461 |
| Rosuvastatin Calcium | 425 | $6,814 |
| Sildenafil Citrate | 18 | $5,615 |
| Ezetimibe | 139 | $5,105 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Los Angeles
- Jon KobashigawaLos Angeles$539K
- Michael FongLos Angeles$361K
- Ajay VaidyaLos Angeles$284K
- Eugene DepasqualeLos Angeles$197K
- Joseph RahmanLos Angeles$131K
- Aaron WolfsonLos Angeles$101K
- Ronald WittelesStanford$4.1M
- James Heywoodla Jolla$2.1M
- Eldrin LewisStanford$1.8M
- Richard WrightSanta Monica$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.